Silo pharma initiates pharmacokinetic and tolerability study for sp-26 targeting chronic pain and fibromyalgia

Key preclinical milestone for novel, non-opioid extended-release pain therapeutic   sarasota, fl, dec. 18, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the initiation of a pharmacokinetic (pk) and tolerability study in partnership with its contract research organization (cro), amplifybio. the study is designed to assess the pharmacokinetics of silo's dissolvable ketamine-based injectable implant, sp-26, in a minipig model.
SILO Ratings Summary
SILO Quant Ranking